MAKING THE PRESS
Mary Crowley Cancer Research (MCCR) announced today the addition of Rodney Olsen to their Board of Directors.
Mary Crowley Cancer Research (MCCR) announced today the addition of Edward Marx to their Board of Directors.
The prostate is a hormonally regulated organ and prostate cancer is reliant on androgen receptor signaling for growth. The treatment of advanced prostate cancer has thus traditionally focused on the inhibition of androgen signaling (for example through blockade of the androgen receptor, or inhibition of testosterone production). In the majority of cases, however, the prostate cancer will adapt to low androgen states and become castrate-resistant.
A message from our Chairman of the Board Roy Lamkin.
The Be the Difference Foundation presented Runway for Hope, a luncheon and fashion show benefiting Mary Crowley Cancer Research on September 26th. This speech was given by Be the Difference co-founder, Runway for Hope co-chair, and ovarian cancer survivor Lynn Lentscher.
